Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
TG Therapeutics, Inc., a prominent biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with B-cell malignancies and autoimmune diseases. Founded in 2012, the company has made significant strides in the industry, particularly with its unique approach to targeted therapies that leverage the power of monoclonal antibodies and small molecules.
With a strong presence in the oncology and autoimmune sectors, TG Therapeutics has achieved notable milestones, including the advancement of its lead product candidates, which aim to improve treatment outcomes for patients. The company is recognised for its commitment to research and development, positioning itself as a leader in the biopharmaceutical landscape. Through its dedication to innovation, TG Therapeutics continues to make a meaningful impact on patient care and treatment options.
-19 vs industry average
TG Therapeutics, Inc.’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for TG Therapeutics, Inc. yet.
TG Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as there are no available figures for their emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges.
As of now, TG Therapeutics does not inherit emissions data from a parent company, nor does it have any cascading targets from related organisations. This lack of data and commitments places the company in a position where it may need to enhance its climate strategy to align with industry standards and expectations for sustainability.
In the absence of specific emissions figures or reduction initiatives, it is crucial for TG Therapeutics to consider developing a comprehensive climate action plan to address potential environmental impacts and contribute positively to global climate goals.
No climate goals have been disclosed for TG Therapeutics, Inc. yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more